Novel Experimental Drug Improves Survival for Advanced Pancreatic Cancer Patients

A recent study indicates that an experimental daily pill significantly extends the lives of patients with advanced pancreatic cancer, particularly those whose disease no longer responds to standard treatments. The drug reportedly reduced the risk of death by 60% and nearly doubled overall survival rates. These promising results have prompted the FDA to fast-track its review process and implement an expanded access program, allowing eligible patients early access to the medication.